IPRIPR2023-01312Terminated-Adverse Judgment
Samsung Bioepis Co., Ltd.v.REGENERON PHARMACEUTICALS, INC.
IPR challenge of US 10464992.
Type
IPR
Filed
Aug 18, 2023
Instituted
Dec 8, 2023
Decided
Feb 21, 2024
Patent
Application
16159269
Inventor
Eric FURFINE et al
Granted
Nov 5, 2019
01
Timeline
3 milestones
2023-08-18Petition filed
2023-12-08Institution
2024-02-21Terminated
02
Parties & counsel
Petitioner
Samsung Bioepis Co., Ltd.
Counsel
Nimrod, Raymondet al
Patent Owner
REGENERON PHARMACEUTICALS, INC.
Counsel
Brausa, Adamet al
03
Docket
Documents are mirrored from the PTAB e-file system. Filer is as stated on the face of the filing.
SOURCE · USPTO PTAB E2EView on Unified Patents →